Merck to build $55m German plant for its allergy business

- Last updated on GMT

Allergopharma - a subsidiary of Merck KGaA - building new allergy treatment plant
Allergopharma - a subsidiary of Merck KGaA - building new allergy treatment plant

Related tags: Asthma

Merck KGaA subsidiary Allergopharma has begun construction on a €40m ($55m) facility to produce products for type 1 allergies.

The site, in Reinbek near Hamburg, Germany will have an area of more than 6,000m2​ containing cleanrooms for production, as well as plant engineering technology, and is being built - in part - to expand production of allergy therapies in new markets, including China.

The firm’s Allergen-specific immunotherapy involves administering increasing doses of allergens with the aim of improving the allergic response and is, according to Allergopharma, the only causal treatment for allergies to unavoidable allergens available.

“We want to fully exploit the potential of our business, whether in Emerging Markets or in rapidly growing and highly promising areas such as the global allergy market,”​ Stefan Oschmann, a Merck executive board member said.

“With this investment, which is largest in the history of Allergopharma, Merck is setting an important milestone to expand the Allergy business internationally and to secure the future of the Reinbek site.”

The facility is expected to be completed in 2016 and will employ, initially, 40 people.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more